Anticancer activity, apoptosis and a structure-activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides [0.03%]
一类1,4-萘醌-2,3-双硫醚衍生物的抗肿瘤活性、促凋亡作用及其构效关系研究
Kevin W Wellington,Natasha I Kolesnikova,Vincent Hlatshwayo et al.
Kevin W Wellington et al.
We have previously reported on the synthesis of 1,4-naphthoquinone-sulfides and in this investigation we report on their anticancer activity against 6 human cancer cell lines to evaluate their cytostatic effects. The 1,4-naphthoquinone-2,3-...
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors [0.03%]
ivosidenib（一种口服型靶向IDH1突变抑制剂）在晚期实体瘤患者中的临床药动学和药效学研究
Bin Fan,Ingo K Mellinghoff,Patrick Y Wen et al.
Bin Fan et al.
Background Mutant isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a targeted mutant IDH1 inhibitor under evaluation in a phase 1 dose escalation and expansi...
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma [0.03%]
节拍式全口服DEVEC方案可有效治疗老年弥漫大B细胞淋巴瘤患者
M Christina Cox,Sabrina Pelliccia,Luigi Marcheselli et al.
M Christina Cox et al.
Metronomic-chemotherapy (M-CHT) has been rarely assessed in non-Hodgkin-lymphoma (NHL). Therefore, in 2011 we started experimenting a new all-oral M-CHT schedule termed DEVEC (Deltacortene®, etoposide, vinorelbine, cyclophosphamide, +/-Rit...
Multicenter Study
Investigational new drugs. 2019 Jun;37(3):548-558. DOI:10.1007/s10637-019-00769-5 2019
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial [0.03%]
曲拉西利用于预防接受含卡铂化疗的转移性三阴乳腺癌患者骨髓抑制的中国人群药代/暴露-反应和安全性分析：I期临床试验结果
Kenichi Inoue,Jun Ninomiya,Tsuyoshi Saito et al.
Kenichi Inoue et al.
The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.
Published Erratum
Investigational new drugs. 2019 Jun;37(3):592-593. DOI:10.1007/s10637-019-00773-9 2019
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer [0.03%]
西妥昔单抗联合U3-1565（反义-肝素结合表皮生长因子样生长因子）治疗对西妥昔单抗或帕尼单抗耐药的转移性结直肠癌患者I期临床试验
Takako Eguchi Nakajima,Narikazu Boku,Ayako Doi et al.
Takako Eguchi Nakajima et al.
KRAS wild-type colorectal cancers initially responsive to anti-endothelial growth factor receptor (EGFR) antibodies [cetuximab (Cetu)/panitumumab (Pani)] develop acquired resistance. Overexpression of EGFR ligands such as heparin-binding EG...
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors [0.03%]
评估cobimetinib(GDC-0973)与pictilisib(GDC-0941)联合治疗晚期实体瘤的Ib期临床研究
Geoffrey I Shapiro,Patricia LoRusso,Eunice Kwak et al.
Geoffrey I Shapiro et al.
Purpose We investigated the combination of the MEK inhibitor, cobimetinib, and the pan-PI3K inhibitor, pictilisib, in an open-label, phase Ib study. Experimental Design Patients with advanced solid tumors were enrolled in 3 dose escalation ...
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma [0.03%]
移除派姆单抗的吉西他滨和白蛋白结合型紫杉醇治疗转移性胰腺导管腺癌 Ib/II 期临床试验的更正公告
Glen J Weiss,Lisa Blaydorn,Julia Beck et al.
Glen J Weiss et al.
The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS v...
Published Erratum
Investigational new drugs. 2019 Aug;37(4):797. DOI:10.1007/s10637-019-00763-x 2019
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma [0.03%]
硫链酶素的抗鼻咽癌作用及其机制研究
Yen-Bin Hsu,Ming-Chin Lan,Yu-Lun Kuo et al.
Yen-Bin Hsu et al.
Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the a...
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors [0.03%]
一项针对CD30阳性实体瘤患者的brentuximab vedotin二期、开放标记临床试验
Jeffrey P Sharman,Jennifer J Wheler,Lawrence Einhorn et al.
Jeffrey P Sharman et al.
Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. Th...
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB [0.03%]
核仁蛋白沉默增强黄酮素芹菜素的抗前列腺癌症干细胞活性：通过ERK、p38、PTEN、PARP和NF-κB调控信号通路的合作作用
Suat Erdogan,Kader Turkekul,Ilker Dibirdik et al.
Suat Erdogan et al.
Prostate cancer (PCa) is the most common cancer in men worldwide. Midkine (MK) is overexpressed in PCa, as well as in tumor-initiating cells termed cancer stem cells (CSCs). Apigenin is a dietary flavone with considerable anti-tumor activit...